Acute respiratory distress syndrome (ARDS) is a clinical condition characterized by acute
diffuse inflammatory lung injury and severe hypoxemia. In 2017, the Montreux Consensus …

Both prophylactic and early surfactant (SF) replacement therapy reduce pulmonary
complications and mortality in ventilated infants with respiratory distress syndrome (RDS) …

Background In addition to surfactant deficiency, increase of lung fluid content and secretion
of fluid derived from the blood participate in the pathogenesis of RDS in newborns. We …

For preterm infants with respiratory distress syndrome, delivery of surfactant via brief
intubation (INtubate, SURfactant, Extubate; InSurE) has been the standard technique of …

Aim: Pneumonia in childhood may be associated with surfactant dysfunction and severe
acute respiratory distress syndrome (ARDS). The aim of this study was to investigate the …

Pediatric (PARDS) and neonatal (NARDS) acute respiratory distress syndrome have
different age-specific characteristics and definitions. Trials on surfactant for ARDS in children …

Background. The significant advancement in the treatment of respiratory distress syndrome
can be attributed to prenatal identification of high risk pregnancies, prevention of illness …

Acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome that lacks
definitive treatment. The cornerstone of management is sound intensive care treatment and …

Acute respiratory distress syndrome (ARDS) is a heterogeneous syndrome that lacks
definitive treatment. The cornerstone of management is sound intensive care treatment and …

Background Neonatal respiratory distress syndrome (NRDS), if caused by a lack of
pulmonary surfactant (PS), leads to progressive alveolar collapse. Glucocorticoids have anti …